Phosphatidylinositol 5-phosphate 4-kinase type-2 (PIP4K2)

Phosphatidylinositol 5-phosphate 4-kinase type-2 (PIP4K2) is a family of lipid kinases, comprising alpha (PIP4K2A), beta (PIP4K2B), and gamma (PIP4K2C) isoforms, that catalyze the phosphorylation of phosphatidylinositol 5-phosphate (PI5P) to generate phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) [1, 8]. Unlike the type-1 kinases (PIP5K) that utilize PI4P as a substrate, PIP4K2 enzymes are unique in their substrate specificity and their ability to act as cellular GTP sensors, linking the cell's metabolic state to signaling pathways [3, 12]. These enzymes are critical regulators of the PI3K/AKT/mTOR pathway and autophagy, influencing cell survival, growth, and nutrient sensing [6, 10]. In various cancers, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and breast cancer, PIP4K2 isoforms are frequently overexpressed and support tumor cell proliferation and resistance to apoptosis [2, 8, 10]. Consequently, PIP4K2 has emerged as a promising therapeutic target, with several small-molecule inhibitors and degraders currently in preclinical development [11, 13, 16]. Beyond oncology, the family's role in insulin signaling and metabolic homeostasis suggests potential therapeutic utility in treating type 2 diabetes and neurodegenerative conditions [6, 9]. Inhibition of PIP4K2 leads to the accumulation of PI5P, which can modulate the activity of proteins like AKT and the tumor suppressor p53 [5, 17]. The development of isoform-selective inhibitors remains a key area of research to minimize potential side effects related to the broad biological roles of these kinases [13, 16].

Other names

PI5P4KPIP5K2PIPKII1-phosphatidylinositol 5-phosphate 4-kinaseDiphosphoinositide kinase type II

PIP4K2 inhibitors function by selectively binding to the active site of the enzyme, preventing the phosphorylation of phosphatidylinositol 5-phosphate (PI5P) to phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). This leads to an accumulation of PI5P and a reduction in PI(4,5)P2 levels, which modulates downstream signaling pathways such as PI3K/AKT/mTOR and autophagic flux.